Thermoactinomyces vulgaris, IgG Antibodies, Serum
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Evaluating patients suspected of having hypersensitivity pneumonitis induced by exposure to this antigen
Fluorescence Enzyme Immunoassay (FEIA)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Thermoactinomyces vulgaris, IgG Ab
Specimen Type Describes the specimen type needed for testing
Specimen Required Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.
Preferred: Red top
Acceptable: Serum gel
Specimen Volume: 0.5 mL
Specimen Minimum Volume Defines the amount of specimen required to perform an assay once, including instrument and container dead space. Submitting the minimum specimen volume makes it impossible to repeat the test or perform confirmatory or perform reflex testing. In some situations, a minimum specimen volume may result in a QNS (quantity not sufficient) result, requiring a second specimen to be collected.
Mild OK; Gross OK
Mild OK; Gross OK
Specimen Stability Information Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.
|Serum||Refrigerated (preferred)||14 days|
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Thermoactinomyces vulgaris is a causative agent of hypersensitivity pneumonitis (HP). Other causative microorganisms include Micropolyspora faeni and Aspergillus fumigatus. While the immunopathogenesis of HP is not known, several immune mechanisms are postulated to play a role, including both cellular and humoral mechanisms.(1)
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
0-12 years: < or =6.6 mg/L
13-18 years: < or =11.0 mg/L
>18 years: < or =23.9 mg/L
Elevated concentrations of IgG antibodies to Thermoactinomyces vulgaris are consistent with the diagnosis of hypersensitivity pneumonitis (HP) caused by exposure to this antigen.
Elevated concentrations of IgG antibodies to Thermoactinomyces vulgaris were found in a small number of sera from patients with HP (4%).(2)
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
IgG antibodies to Thermoactinomyces vulgaris are detectable in healthy individuals, and the presence of antibodies is not sufficient to establish the diagnosis of hypersensitivity pneumonitis (HP) caused by exposure to this antigen.
The levels of antibodies decrease following successful treatment of HP; but, elevated levels may persist for long periods.
Clinical Reference Provides recommendations for further in-depth reading of a clinical nature
1. Fink JN, Zacharisen MC: Hypersensitivity pneumonitis. In Allergy Principles and Practice. Vol. 1. 5th edition. Edited by E Middleton Jr, CE Reed, EF Ellis, et al. St. Louis, MO, Mosby Year Book Inc., 1998, Chapter 19
2. Anderson E, Jacob GL, Roberts GD, Homburger HA: Comparative evaluation of enzyme immunoassay and immunodiffusion for detection of IgG antibodies to hypersensitivity pneumonitis antigens. Poster Presentation AAAAI Annual Meeting, San Diego, CA, March 3-8, 2000. J Allergy Clin Immunol 2000;105:S304
Method Description Describes how the test is performed and provides a method-specific reference
The Phadia CAP System specific IgG FEIA provides an in vitro method for measuring the levels of circulating specific IgG antibodies in human blood samples. Specific IgG from the patient's serum reacts with the antigen of interest, which is covalently coupled to an ImmunoCAP. After washing away non-specific IgG, enzyme labeled anti-IgG antibodies are added to form a complex. After incubation, unbound enzyme-anti IgG is washed away and the bound complex is then incubated with a developing agent. After stopping the reaction, the fluorescence of the eluate is measured. The fluorescence is proportional to the amount of specific IgG, which is present in the patient's sample, ie, the higher the fluorescence value, the more specific IgG antibody is present.
Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.
Monday through Friday; 9 a.m.-8 p.m.
Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.
Same day/1 day
Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result
Specimen Retention Time Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location The location of the laboratory that performs the test
Test Classification Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer's instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR), Investigation Use Only (IUO) product, or a Research Use Only (RUO) product.
This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.
CPT Code Information Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
LOINC® Code Information Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.
|Result ID||Reporting Name||LOINC Code|
|TAMV||Thermoactinomyces vulgaris, IgG Ab||34190-9|